Welcome to our dedicated page for Hims & Hers Health news (Ticker: HIMS), a resource for investors and traders seeking the latest updates and insights on Hims & Hers Health stock.
Hims & Hers Health, Inc. reports news about its consumer telehealth platform, which connects customers with providers and offers treatment options across areas such as sexual health, hair loss, skin care, mental health and weight loss. Company updates commonly cover prescription access, FDA-approved GLP-1 weight loss medications, platform memberships, subscriber benefits and health-and-wellness partner programs.
Recurring developments also include operating and financial results, conference participation, board and executive appointments, shareholder voting matters, governance updates and clinical or regulatory disclosures tied to products available through the Hims and Hers platform.
Hims & Hers Health, Inc. (NYSE: HIMS) has expanded its Medical Advisory Board by adding five new members specializing in obesity, menopause, and cardiometabolic health. This initiative aims to enhance access to personalized healthcare and improve clinical quality. Chief Medical Officer Dr. Pat Carroll emphasized that the new members will play a crucial role in guiding treatment protocols and ensuring adherence to clinical standards. Hims & Hers seeks to evolve its product offerings to provide efficient and high-quality care to its customers as part of its mission to enhance health and wellness.
Allermi, a telehealth service specializing in customized allergy relief, has secured $3.5 million in seed funding, led by Nelstone Ventures and FourSight Capital Partners. This funding aims to support Allermi's expansion across the U.S., enhancing marketing and product operations. Launched in July 2022 with a $1.25 million pre-seed investment, Allermi has experienced rapid growth, increasing by over 30% month-over-month. The company offers a unique nasal spray tailored to patients' specific allergy symptoms, reporting over 90% patient satisfaction. Additionally, Allermi is providing a free trial for new patients.
Hims & Hers Health, Inc. (NYSE: HIMS) has launched the Hims Dandruff Detox shampoo, designed in collaboration with doctors to combat dandruff while promoting scalp health. This vegan, cruelty-free formula is free from parabens, phthalates, sulfates, and dyes. Dandruff affects nearly 50% of the population, and this new offering addresses hair loss linked with dandruff through key ingredients like zinc pyrithione and Argan oil. The product is now available online and at retailers such as CVS and Amazon. Hims & Hers continues to expand its hair care line, which includes various men's grooming products and prescription options.
Hims & Hers Health, Inc. (NYSE: HIMS) has responded to the liquidity concerns surrounding Silicon Valley Bank (SVB), stating that it has limited cash exposure due to the ongoing situation. Most of the company's cash and short-term investments are secured with third-party custodians not associated with SVB. Furthermore, Hims & Hers confirms it has no debts or current lines of credit affected by these developments. The company continues to focus on its mission to provide personalized health and wellness solutions.
Hims & Hers Health reported revenue of $526.9 million for 2022, marking a 94% increase year-over-year. In Q4 2022, revenue reached a record $167.2 million, up 97% from Q4 2021, with an adjusted EBITDA of $3.9 million despite a net loss of $10.9 million. The company surpassed one million subscribers, an 88% growth from the previous year. For 2023, Hims & Hers projects revenue between $735 million and $755 million and aims for adjusted EBITDA of $20 million to $30 million. Looking ahead, the company targets at least $1.2 billion in revenue and $100 million in adjusted EBITDA by 2025.
Hims & Hers Health, Inc. has launched Hard Mints, a prescription chewable tablet designed for erectile dysfunction. These mint-flavored tablets utilize active ingredients found in popular medications like Cialis© and Viagra©, providing a personalized treatment option. Priced from $30 per month, Hard Mints come in various dosages, allowing for tailored healthcare solutions. The introduction of this product is part of Hims & Hers' commitment to innovating personalized health treatments, aiming to enhance patient confidence and improve access to necessary medications.
Hims & Hers Health, Inc. (NYSE: HIMS) will report its fourth quarter and full year 2022 financial results on February 27, 2023, after market close. A conference call is scheduled for 5:00 p.m. ET that same day to discuss the results. Participants can join by dialing (888) 510-2630 for U.S. callers or (646) 960-0137 for international attendees, using conference ID 1704296. The call will also be available via a live audio webcast, which will be archived for one year on the company's investor relations website.
Additionally, Hims & Hers management will participate in several upcoming investor conferences in March 2023, including events hosted by Citi, JMP Securities, and KeyBanc.
Hims & Hers Health, Inc. (NYSE: HIMS) has launched a new line of volumizing shampoos and conditioners, formulated with Biovolume 128™ to enhance hair volume. These vegan and cruelty-free products target individuals with fine or limp hair. Notably, the new items include Hims Max Volume Shampoo and Conditioner, and Hers Full Volume Shampoo and Conditioner, featuring ingredients like Biotin and Hydrolyzed Rice Protein. Available for purchase at ForHims.com, ForHers.com, and retailers like Walgreens, this expansion adds to the company's existing hair care offerings. Hims & Hers aims to provide personalized health solutions for customers.
Hims & Hers Health announces the return of Dr. Pat Carroll as Chief Medical Officer, aimed at enhancing clinical operations and patient care. Under his leadership, the company has reported unprecedented growth, nearing one million subscriptions and achieving a 95% year-over-year revenue increase to $144.8 million. Dr. Carroll's reappointment follows strong quarterly earnings and reflects the company's commitment to innovative, personalized healthcare solutions.
Hims & Hers Health, Inc. (NYSE: HIMS) appointed Dr. Scott Knoer as its first Chief Pharmacy & Innovation Officer, focusing on pharmacy strategy and innovation. With over two decades of experience, Knoer previously served as the Chief Pharmacy Officer at Cleveland Clinic and CEO of the American Pharmacists Association. Hims & Hers reported strong Q3 2022 results with a 95% revenue increase to $144.8 million and 170,000 new subscriptions, bringing total subscriptions to 991,000. The company is expanding its pharmacy operations with new facilities in Ohio and Arizona.